Phase Ib RCT in 46 healthy adults primed with rVSVΔG-ZEBOV-GP: INO-4201 DNA booster vs placebo had similar adverse events at 14 days (56% vs 50%; RR 1.11) and no serious events; in vaccinees, EBOV-GP-binding titres rose from 704.3 to 3221.7 at 4 weeks.
RCTn = 46
Huttner et al. A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV)